NCT05098470View on ClinicalTrials.gov

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

July 29, 2025

Study Completion Date

July 29, 2026

Conditions
Type 2 Diabetes
Interventions
DRUG

Metformin

1500-2000 mg per day for 8 weeks

DRUG

Insulin Glargine

Long-acting insulin for 8 weeks

DRUG

Dorzagliatin

Oral Glucokinase Activator 75 mg twice daily for 8 weeks

Trial Locations (2)

22908

University of Virginia, Charlottesville

35294

Rita Basu, Birmingham

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Alabama at Birmingham

OTHER